GLP-1 Peptide Atlas, by Delfa

WithdrawnPhase 2

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

—

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≥27

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06901349

Org study ID27328

Secondary IDJ4Z-MC-GIDIEli Lilly and Company

Timeline

Milestones

Study first posted2025-03-28actual

Study start2025-05-23actual

Primary completion2025-06-10actual

Study completion2025-06-10actual

Last update posted2025-09-24actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have type 2 diabetes

•Have a BMI of ≥27 kilograms per square meter (kg/m2)

•Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion criteria

•Have a prior or planned surgical treatment for obesity,

•Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma

•Have poorly controlled hypertension

•Have any of the following cardiovascular conditions within 3 months prior to screening:

–acute myocardial infarction

–cerebrovascular accident (stroke)

–unstable angina, or

–hospitalization due to congestive heart failure

•Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure

•Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes

•Have ongoing or a history of bradyarrhythmias other than sinus bradycardia

•Have renal impairment

•Have a history of symptomatic gallbladder disease within the past 2 years

•Have signs and symptoms of any liver disease

•Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality

•Have a history of acute or chronic pancreatitis

•Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Endpoints (16)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Cardiometabolic biomarkers

Glycemic / diabetes

MASH / liver

Safety / tolerability / PK

Weight & body composition

9 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 36

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA)

Time frame:Baseline, Week 36

Total fat mass

percent change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving ≥5% Body Weight Reduction

Time frame:Baseline, Week 36

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving ≥10% Body Weight Reduction

Time frame:Baseline, Week 36

≥10% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Achieving ≥15% Body Weight Reduction

Time frame:Baseline, Week 36

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Change from Baseline in Waist Circumference

Time frame:Baseline, Week 36

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Mass Index (BMI)

Time frame:Baseline, Week 36

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Waist-to-Height Ratio (WHtR)

Time frame:Baseline, Week 36

change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Visceral Adipose Tissue (VAT) by Magnetic Resonance Imaging (MRI)

Time frame:Baseline, Week 36

Visceral fat, change

percent change from baseline, improvement

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 36

HbA1c, change

change from baseline, improvement

LOINC 4548-4

MASH / liver

1 endpoint

Secondary/protocol endpoint

Change from Baseline in Liver Fat by MRI

Time frame:Baseline, Week 36

Liver fat content, change

change from baseline, improvement

Cardiometabolic biomarkers

4 endpoints

Secondary/protocol endpoint

Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

Time frame:Baseline, Week 36

hs-CRP, change

percent change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Percent Change from Baseline in Total Cholesterol

Time frame:Baseline, Week 36

Total cholesterol, change

percent change from baseline, improvement

LOINC 2093-3

Secondary/protocol endpoint

Percent Change from Baseline in Triglycerides (TG)

Time frame:Baseline, Week 36

Triglycerides, change

percent change from baseline, improvement

LOINC 2571-8

Secondary/protocol endpoint

Change from Baseline in Systolic Blood Pressure (SBP)

Time frame:Baseline, Week 36

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC-ss) of Bimagrumab

Time frame:Predose through Week 52

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.